Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: eico20 who wrote (1487)	9/10/2015 9:07:35 AM
From: oldcoach19	Read Replies (1) \| Respond to of 2026

Femprox deal for U.S. rights next?

To: eico20 who wrote (1487)	9/10/2015 9:55:24 AM
From: Mirror Image	Respond to of 2026

Upon the Food and Drug Administration's ("FDA") acceptance of a New Drug Application ("NDA") for Vitaros, Allergan may elect to exercise its one time opt-in right to assume all future marketing and selling activities in the United States in exchange for certain financial considerations. Read more: http://www.benzinga.com/news/15/09/5827686/apricus-biosciences-enters-into-license-agreement-with-allergan-for-the-u-s-right#ixzz3lLL1Q5VL Note - Upon Acceptance - It's not even upon approval. Basicallly - Apricus - does all the clinical and regulatory that is left for the FDA to accept the NDA and then Allergen has the option to take back the U.S. rights for Vitaros. I doubt that this deal cost us anything upfront - Which is REAL good! I would also think that they somehow tied in the Room temperature Version in the future deal and expect that we would be "paid" if they take the Vitaros rights back.